The Prescription of Success: Improving Pipelines, Increasing Capabilities - Research Report on Globus, Akorn, Anika, Orthofix and Sangamo Biosciences

Tue Mar 5, 2013 8:01am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130305:nPn3055993


NEW YORK,  March 5, 2013  /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Globus
Medical Inc (NYSE: GMED), Akorn, Inc. (NASDAQ: AKRX), Anika Therapeutics, Inc.
(NASDAQ: ANIK), Orthofix International NV (NASDAQ: OFIX) and Sangamo
Biosciences, Inc. (NASDAQ: SGMO). Today's readers may access these reports free
of charge - including full price targets, industry analysis and analyst ratings
- via the links below.

Globus Medical Inc Research Report

Globus delivered a strong year with worldwide sales of  $386 million, up 16.4
percent from 2011. The company was also able to increase its diluted EPS by 46.7
percent over the fourth quarter. Globus Chairman and CEO  Dave Demski  was
pleased with the company's revenue growth, profitability, and strong IPO and
product developments. Globus continues to invest in expanding its facilities to
drive growth. It is also expanding globally, establishing its presence in 24
countries. Because of its strong growth prospects,  Piper Jaffray  raised their
price target on Globus to  $22. They currently maintain an Overweight rating.
The Full Research Report on Globus Medical Inc - including full detailed
breakdown, analyst ratings and price targets - is available to download free of
charge at: [http://www.Investors-Alliance.com/r/full_research_report/09f5_GMED]
- Bad link

--

Akorn, Inc. Research Report

Shares for Akorn rallied by more than 6.5 percent after the company reported its
fourth quarter earnings. Akorn's profit climbed 54 percent, as acquisitions and
newly approved products helped improve revenue. The company's adjusted earnings
of  13 cents  per share beat analysts' estimates by a cent. To continue its
strong momentum, Akorn is planning to further invest in R&D while expanding its
facilities in  India  to build new capacities. Akorn's R&D pipeline includes 56
abbreviated new drug applications (ANDA), with combined annual addressable IMS
market size of about  $5.8 billion. The company is on its way to file 10
additional products in the near future. The Full Research Report on Akorn, Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/60e9_AKRX]

--

Anika Therapeutics, Inc. Research Report

Anika Therapeutics gave investors a reason to celebrate after reporting fourth
quarter revenue that increased 23 percent and earnings that jumped 48 percent.
The strong growth was attributed to the strong sales for orthovisc, the
company's flagship orthiobiologics product. Orthovisc closed the year as the
market leading product. The company is also taking steps for the regulatory
approval of Monovisc. The company intends to improve its manufacturing
capabilities in order to meet the high level of demand for its products. Its
promising pipeline is also another reason to be excited. The Full Research
Report on Anika Therapeutics, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/25da_ANIK]

--

Orthofix International NV Research Report

Orthofix CEO  Robert Vaters  purchased 3000 shares at a price of  $35.97,
showing his confidence in his company's prospects. Following his purchase,
shares for Orthofix moved up by almost 3 percent. Vaters has expressed his
desire to overcome near-term challenges and improve the company's margins. A
better financial standing would allow the company to further develop its
pipeline and drive growth. In the coming year, the company expects constant
currency net sales growth from 1 to 3 percent over 2012. The Full Research
Report on Orthofix International NV - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/a593_OFIX]

--

Sangamo Biosciences, Inc. Research Report

Shares for Sangamo Biosciences rose by 9.45 percent after a Lazard Capital
Markets analyst started coverage on the company with a Buy rating and a price
target of  $16  per share. The analyst noted that the company's products could
be "a big step forward for gene therapy." He also commended the company's effort
to study drugs that have limited treatment options. The company is expecting to
report data from mid-stage clinical trials for HIV and AIDS within the year.
Earlier this month, the company reported fourth quarter revenue of  $8.9 million
 compared to  $4.7 million  in the fourth quarter of 2011. The Full Research
Report on Sangamo Biosciences, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/4ad5_SGMO]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to realize
that the ship has long sailed? You need a strong, informative community in your
arsenal. Join the group that has been consistently identifying momentous
situations as they develop - long before they become the next top news on major
financial networks.

Contact:  Patricia Byers

Email:  press@Investors-Alliance.com

Main: +1-480-745-7826

SOURCE  Investors-Alliance

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.